

July 30, 2025

To,
The Listing Department,
BSE LIMITED,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai- 400 001

To,
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C-1,
G-Block, Bandra Kurla Complex,
Mumbai -400051

Scrip Code: 543349**NSE Symbol: ACUTAAS**

Subject: Press Release pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release discussing the financial results of first quarter ended as on June 30, 2025.

This Press Release will be available on the website of the Company www.acutaas.com.

Kindly take the same on record.

Yours faithfully,

For, ACUTAAS CHEMICALS LIMITED

Ekta Kumari Srivastava
Company Secretary & Compliance Officer



Encl: Press Release

Acutaas Chemicals Limited reports Q1 FY26 Results

Q1 FY26 Revenue from Operation at ₹ 2,072mn, up 17.3% YoY

Q1 FY26 EBITDA Margin Expanded by 785bps YoY to 24.6%

Surat, July 30, 2025: Acutaas Chemicals Limited (BSE: 543349, NSE: ACUTAAS), a leading global manufacturer of advance pharmaceutical intermediates and speciality chemicals, today announced financial results for the quarter ended June 30, 2025.

Consolidated Financial Results – Q1 FY26:

Particulars (Rs. Mn)	Q1FY26	Q1FY25	YoY	Q4FY25	QoQ
Revenue from Operations	2,072	1,767	17.3%	3,085	(32.8%)
Gross Profit	1,103	743	48.4%	1,460	(24.4%)
Gross Margin	53.2%	42.1%		47.3%	
EBITDA	509	295	72.4%	850	(40.1%)
EBITDA Margin	24.6%	16.7%		27.5%	
PAT	440	147	199.6%	627	(29.8%)
PAT Margin	21.2%	8.3%		20.3%	

Commenting on results, Mr. Naresh Patel, Executive Chairman & Managing Director, Ami Organics Limited, said: *"I am happy to share that we've had a strong start to FY26, with Q1 revenue growing 17.3% year-on-year, driven by robust performance in our Pharmaceutical Intermediates business. Both our pharma facilities are now PMDA GMP certified, underscoring our commitment to global compliance and quality.*

I am happy to announce that we have entered into a joint venture in South Korea which brings us closer to key semiconductor markets and strengthens our portfolio with differentiated, high-value products tailored for this space. With rising customer engagement across CDMO, battery chemicals, and semiconductors, we step into FY26 with strong momentum and confidence to deliver 25% growth with improved margins."

Key Results & Business Highlights (Q4FY25 Consolidated):

- ✓ **Revenue from operations** for Q1FY26 grew by **17.3% YoY to Rs. 2,072 mn**
- ✓ The **gross margin** for the quarter improved to **53.2%** up 1,117 bps YoY
- ✓ **EBITDA** for the quarter came at **Rs. 509 mn** up 72.4% YoY
- ✓ **EBITDA margin** for the quarter was at **24.6%** as compared to 16.7% in Q1FY25
- ✓ **PAT** for the quarter was **Rs. 440 mn** up 199.6% as compared to PAT of Rs. 147 mn in Q1FY25
- ✓ The **PAT margin** for the quarter was at **21.2%** up 1,292 bps YoY
- ✓ Export for the quarter at **60%**; domestic business at **40%**

ABOUT ACUTAAS CHEMICALS LIMITED:

Acutaas Chemicals Limited is a speciality chemicals manufacturer serving a wide range of industries, including pharmaceuticals, semiconductors, battery chemicals, personal care, agrochemicals, and fine chemicals. Our core strength lies in the research-driven development and manufacturing of advanced pharmaceutical intermediates used in both regulated and generic APIs, as well as intermediates for New Chemical Entities (NCEs).

We are also expanding our portfolio to include high-value speciality chemicals for emerging technologies such as battery materials, semiconductor, and next-generation electronic applications. In addition, our offerings include parabens and their formulations, methyl salicylate, and niche key starting materials (KSMs) used in cosmetics and other industrial segments.

CAUTIONARY STATEMENT:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Ami Organics has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

PRESS RELEASE

For Immediate dissemination



For details, please contact:

Investor Relations at Acutaas Chemicals Limited

Ekta Srivastava, Company Secretary &
Compliance Officer

cs@acutaas.com

Senior Manager – Investor Relations

Mr. Rahul Thakur

Rahul.thakur@acutaas.com

Registered Office

Plot no. 440/4, 5 & 6, Road No. 82/A,

GIDC Sachin, Surat- 394230

CIN: L24100GJ2007PLC051093

ISIN: INE00FF01025

NSE Code: ACUTAAS

BSE CODE: 543349

Website: www.acutaas.com